Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+0.02%
|
-
|
|
Jan 02
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,647
+2.08%
|
-
|
|
Jan 02
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,907
+1.73%
|
-
|
|
Dec 19
2024
|
Ben R Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
370,343
+30.49%
|
-
|
|
Dec 17
2024
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-1.47%
|
$42,342
$6.95 P/Share
|
|
Dec 16
2024
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,668
-3.16%
|
$94,008
$6.04 P/Share
|
|
Dec 05
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.12 P/Share
|
|
Dec 05
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Dec 04
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.16 P/Share
|
|
Dec 04
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Nov 20
2024
|
Franziska Michor Director |
BUY
Grant, award, or other acquisition
|
Direct |
105,037
+31.26%
|
-
|
|
Nov 15
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,023
-3.41%
|
$156,138
$6.17 P/Share
|
|
Nov 15
2024
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,286
-2.74%
|
$85,716
$6.17 P/Share
|
|
Nov 15
2024
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,937
-0.8%
|
$71,622
$6.17 P/Share
|
|
Nov 15
2024
|
David J Mauro Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,187
-1.82%
|
$25,122
$6.17 P/Share
|
|
Nov 14
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$140,000
$7.35 P/Share
|
|
Nov 14
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Nov 13
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$140,000
$7.74 P/Share
|
|
Nov 13
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Nov 13
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.99%
|
$105,000
$7.66 P/Share
|
|
Nov 13
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.53%
|
$78,750
$2.22 P/Share
|
|
Nov 12
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.01%
|
$105,000
$7.64 P/Share
|
|
Nov 12
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.57%
|
$78,750
$2.22 P/Share
|
|
Nov 12
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$80,129
$7.64 P/Share
|
|
Oct 29
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.72 P/Share
|
|
Oct 24
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
6,000
-1.14%
|
$36,000
$6.31 P/Share
|
|
Oct 24
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.13%
|
$6,000
$1.06 P/Share
|
|
Oct 15
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.67 P/Share
|
|
Oct 09
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.02%
|
$90,000
$6.36 P/Share
|
|
Oct 09
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.62%
|
$78,750
$2.22 P/Share
|
|
Oct 08
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.04%
|
$90,000
$6.32 P/Share
|
|
Oct 08
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.66%
|
$78,750
$2.22 P/Share
|
|
Oct 03
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.08 P/Share
|
|
Oct 03
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Oct 02
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.16 P/Share
|
|
Oct 02
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Oct 01
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,925
+2.48%
|
-
|
|
Oct 01
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,229
+2.06%
|
-
|
|
Oct 01
2024
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,026
+0.03%
|
-
|
|
Oct 01
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.22 P/Share
|
|
Sep 26
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
6,000
-1.14%
|
$42,000
$7.0 P/Share
|
|
Sep 26
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+1.13%
|
$6,000
$1.06 P/Share
|
|
Sep 17
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.84 P/Share
|
|
Sep 11
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.06%
|
$90,000
$6.32 P/Share
|
|
Sep 11
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.7%
|
$78,750
$2.22 P/Share
|
|
Sep 10
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.08%
|
$90,000
$6.17 P/Share
|
|
Sep 10
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.75%
|
$78,750
$2.22 P/Share
|
|
Sep 05
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.14 P/Share
|
|
Sep 05
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Sep 04
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$120,000
$6.04 P/Share
|